Sales and EBITA 2% and 14% vs. ABGSCeCustomer intake flat q-o-q (ABGSCe -2,500)Cons to lift '23e-'25...
Redeye states its view of Bredband2’s Q2 2023 report, released earlier today.
Suominen’s Q2 results showed some improvement in terms of operational efficiency, however top line f...
Suominen reported slightly lower comparable EBITDA than expected, but reiterated its guidance for im...
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA.
Redeye comments on Fantasma Games’ Q2 results, which came in below our expectations.
Q2 report due on Thursday, 17 AugustEBIT down on lowered marginsHopefully more clarity on strategy w...
EPS delivery delayed until Q3 due to Linguacom bankruptcyExpect less of a peak in Q2 as seasonal eff...
NoHo reported Q2 EBIT 13% above Vara consensus, despite 4% lower sales.
Redeye provides its outlook on Respiratorius following its Q2 2023 report.
Infrea redovisade minskad omsättning och resultat i Q2 påverkat av kallare väder.
The ordinary required revaluation of a certain number of patients showed a high level of variability...
NoHo Partners reported Q2 EBIT of EUR 10.7m, +13% versus Vara consensus and +9% versus our estimate.
Redeye comments on GiG ahead of its Q2-results (due 16 August) where we expect continued solid organ...
Redeye provides a preview of Thunderful Group ahead of its Q2 2023 report, due on August 21.
Q2 report due Thursday, 24 August'23e EBITA down 1%, '24e-'25e EBITA up 1%11-9x EBITA '23e-'25e, 12%...
Scanfil’s Q2 results were a bit better than we estimated.
CapMan’s Q2 fell below our expectations and the near-term development outlook remains sluggish.
Redeye provides an update in relation to Optomed’s Q2 2023 report.
Redeye updates on W5 Solutions following a solid Q2-report which was substantially stronger than our...
